LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Pfizer

Slēgts

SektorsVeselības aprūpe

27.73 0.51

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

27.3

Max

27.93

Galvenie mērījumi

By Trading Economics

Ienākumi

-5.2B

-1.6B

Pārdošana

903M

18B

P/E

Sektora vidējais

19.89

121.746

EPS

0.66

Dividenžu ienesīgums

6.32

Peļņas marža

-9.387

Darbinieki

81,000

EBITDA

-6.6B

-930M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+6.88% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

6.32%

2.26%

Nākamie ieņēmumi

2026. g. 28. apr.

Nākamais dividenžu datums

2026. g. 6. marts

Nākamais Ex dividenžu datums

2026. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.2B

154B

Iepriekšējā atvēršanas cena

27.22

Iepriekšējā slēgšanas cena

27.73

Ziņu noskaņojums

By Acuity

42%

58%

126 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Pfizer Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. febr. 12:25 UTC

Peļņas

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

2026. g. 20. janv. 10:40 UTC

Iegādes, apvienošanās, pārņemšana

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

2026. g. 20. janv. 07:47 UTC

Iegādes, apvienošanās, pārņemšana

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

2026. g. 10. febr. 21:51 UTC

Peļņas

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026. g. 10. febr. 21:17 UTC

Peļņas

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026. g. 3. febr. 21:36 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

2026. g. 3. febr. 19:56 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 19:46 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

2026. g. 3. febr. 17:35 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 17:30 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

2026. g. 3. febr. 13:50 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 13:06 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 12:45 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

2026. g. 3. febr. 12:02 UTC

Peļņas

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

2026. g. 3. febr. 11:48 UTC

Peļņas

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

2026. g. 3. febr. 11:48 UTC

Peļņas

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

2026. g. 3. febr. 11:47 UTC

Peļņas

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

2026. g. 3. febr. 11:46 UTC

Peļņas

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer Reaffirms 2026 Guidance >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer 4Q Rev $17.56B >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer 4Q Adj EPS 66c >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer 4Q Loss/Shr 29c >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer 4Q Loss $1.65B >PFE

2026. g. 3. febr. 11:45 UTC

Peļņas

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

2026. g. 3. febr. 10:41 UTC

Peļņas

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

2026. g. 20. janv. 07:13 UTC

Iegādes, apvienošanās, pārņemšana

GSK PLC: Agreement Simplifies ViiV's Shareholder Structure

2026. g. 20. janv. 07:13 UTC

Iegādes, apvienošanās, pārņemšana

GSK PLC to Get Special Div of $0.250B

2026. g. 20. janv. 00:21 UTC

Iegādes, apvienošanās, pārņemšana

Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1B

2026. g. 12. janv. 21:18 UTC

Tirgus saruna

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

Salīdzinājums

Cenas izmaiņa

Pfizer Prognoze

Cenas mērķis

By TipRanks

6.88% augšup

Prognoze 12 mēnešiem

Vidējais 28.91 USD  6.88%

Augstākais 35.46 USD

Zemākais 25 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pfizer  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

18 ratings

6

Pirkt

12

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

22.855 / 23.85Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

126 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat